Gubra awarded grant to develop smart insulin: "We'll become 3-4 times faster"
Gubra has received a research grant from diabetes organization JDRF in order to develop a new type of insulin with the potential to revolutionize the treatment of type 1 diabetes and make other types of insulin obsolete. According to CSO Keld Fosgerau, the project can be expanded to maximize value before getting a partner on board.
Danish biotech company and contract research organization Gubra has entered a new partnership with global diabetes organization JSRF to develop of new type of 'smart' insulin, which has the potential to render obsolete the current mealtime insulin and basal insulin used to treat insulin-dependent diabetes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
